Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Subodh Verma Added: 1 year ago
AHA Conference 2024 - Outcomes of SELECT show that semaglutide treatment in obese or overweight patients with prior history of coronary artery bypass graft (CABG) surgery reduces the risk of cardiovascular events.Dr Subodh Verma (University of Toronto, Toronto, CA) joins us onsite at AHA Conference to discuss the findings from SELECT (NCT03574597).SELECT is a randomized, double-blind, placebo… View more
Author(s): Donna H Ryan Added: 1 year ago
ECO 2024 — Dr Donna H Ryan (Pennington Biomedical Research Center, US) joins us to discuss the first sub-analysis of the landmark SELECT trial (NCT03574597, Novo Nordisk).In this study, investigators looked at long-term weight loss with semaglutide 2.4 mg compared to a placebo among 17,604 participants. In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss compared to… View more
Research Area(s) / Expertise: Job title: Professor, Obesity and Stress Hormone Research
Prof Liesbeth van Rossum, MD PhD, is internist-endocrinologist and professor in the field of obesity and stress hormone research at the Erasmus University Medical Center in Rotterdam, Netherlands. Sheis also co-founder of the Obesity Center CGG, an internationally recognised academic centre of obesity management.Prof Van Rossum holds various societal and board positions, amongst the European lead… View more
Author(s): Helen Colhoun Added: 1 year ago
EASD 24 - We are joined by Dr Helen Coulhoun (University of Edinburgh, UK) to discuss the key findings of a prespecified analysis of the SELECT trial, which investigated the effectiveness of semaglutide in reducing major cardiac events in the presence of impaired kidney function in patients with overweight and obesity.Findings showed that participants in the study with reduced eGFR and/or… View more
Author(s): Nils Krüger Added: 6 months ago
AHA Scientific Sessions 2025 - Dr Nils Krüger (Brigham and Women's Hospital, US) joins us to discuss findings from the TIRZSEMA-CVOT (NCT07096063) study, examining real-world cardiovascular outcomes with tirzepatide and semaglutide in patients with type 2 diabetes at cardiovascular risk.This retrospective cohort study utilized three national US claims databases to evaluate over 887,000 patients… View more
Author(s): Christina Magnussen Added: 1 year ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global… View more
Job title: PhD, RD, FHFSA, FASPEN
Dr Salvatore Carbone, PhD, RDN, MS, FHFSA, FASPEN is an Associate Professor and Program Director of the Nutrition Program at the EVMS School of Health Professions, and an Associate Professor within the EVMS Division of Endocrine and Metabolic Disorders, Strelitz Diabetes Center, Department of Internal Medicine, at the Macon & Joan Brock Virginia Health Sciences at Old Dominion University… View more